Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

Journal of Clinical Investigation

Volumn 118, Issue 2, 2008, Pages 491-504

  Mukherjee, Siddhartha ^a,b,c,d   Raje, Noopur ^a,c   Schoonmaker, Jesse A ^a,d   Liu, Julie C ^e   Hideshima, Teru ^a   Wein, Marc N ^f   Jones, Dallas C ^f   Vallet, Sonia ^a   Bouxsein, Mary L ^a   Pozzi, Samantha ^a   Chhetri, Shweta ^a   Seo, Y David ^a,d   Aronson, Joshua P ^a,d   Patel, Chirayu ^d   Fulciniti, Mariateresa ^a   Purton, Louise E ^a,d   Glimcher, Laurie H ^f   Lian, Jane B ^e   Stein, Gary ^e   Anderson, Kenneth C ^a   Scadden, David T ^a,b,c,d   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d Harvard University   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY OSSICLE; BONE REGENERATION; CELL DIFFERENTIATION; CELL POPULATION; DRUG TARGETING; FEMALE; LYMPHOCYTE TRANSFORMATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROGENY; TRABECULAR BONE;

ANIMALS; BONE REGENERATION; BORONIC ACIDS; CELL DIFFERENTIATION; FEMALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; PROTEASE INHIBITORS; PYRAZINES;

EID: 38849130851     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33102     Document Type: Article

References (43)

1. Friedenstein, A.J., Piatetzky, S., II, and Petrakova, K.V. 1966. Osteogenesis in transplants of bone marrow cells. J. Embryol. Exp. Morphol. 16:381-390.
2. Friedenstein, A.J., Chailakhyan, R.K., Latsinik, N.V., Panasyuk, A.F., and Keiliss-Borok, I.V. 1974. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 17:331-340.
3. Horwitz, E.M., et al. 1999. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5:309-313.
4. Prockop, D.J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 276:71-74.
5. Mangi, A.A., et al. 2003. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9:1195-1201.
6. Ding, S., and Schultz, P. 2005. Small molecules and future regenerative medicine. Curr. Top. Med. Chem. 5:383-395.
7. Shimazaki, C., et al. 2005. High serum bone-specific alkaline phosphatase level after bortezomibcombined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia. 19:1102-1103.
8. Zangari, M., et al. 2005. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br. J. Haematol. 131:71-73.
9. Shen, R., et al. 2006. Smad6 interacts with Runx-2 and mediates Smad ubiquitin regulatory factor 1-induced Runx-2 degradation. J. Biol. Chem. 281:3569-3576.
10. Garrett, I.R., et al. 2003. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 111:1771-1782.
11. Giuliani, N., et al. 2007. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 110:334-338.
12. Meirelles Lda, S., and Nardi, N.B. 2003. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br. J. Haematol. 123:702-711.
13. Sun, S., et al. 2003. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells. 21:527-535.
14. Anjos-Afonso, F., Siapati, E.K., and Bonnet, D. 2004. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J. Cell Sci. 117:5655-5664.
15. Quarto, N., and Longaker, M.T. 2006. FGF-2 inhibits osteogenesis in mouse adipose tissue-derived stromal cells and sustains their proliferative and osteogenic potential state. Tissue Eng. 12:1405-1418.
16. Nakashima, K., et al. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 108:17-29.
17. Rodda, S.J., and McMahon, A.P. 2006. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 133:3231-3244.
18. Jaiswal, N., Haynesworth, S.E., Caplan, A.I., and Bruder, S.P. 1997. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J. Cell Biochem. 64:295-312.
19. Janderova, L., McNeil, M., Murrell, A.N., Mynatt, R.L., and Smith, S.R. 2003. Human mesenchymal stem cells as an in vitro model for human adipogenesis. Obes. Res. 11:65-74.
20. Pittenger, M.F., et al. 1999. Multilineage potential of adult human mesenchymal stem cells. Science. 284:143-147.
21. Dominici, M., et al. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8:315-317.
22. Mundlos, S., et al. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 89:773-779.
23. Otto, F., et al. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 89:765-771.
24. Tintut, Y., Parhami, F., Le, V., Karsenty, G., and Demer, L.L. 1999. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J. Biol. Chem. 274:28875-28879.
25. Gori, F., Thomas, T., Hicok, K.C., Spelsberg, T.C., and Riggs, B.L. 1999. Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. J. Bone Miner. Res. 14:1522-1535.
26. Banerjee, C., et al. 2001. Differential regulation of the two principal Runx-2/Cbfa1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype. Endocrinology. 142:4026-4039.
27. Jones, D.C., et al. 2006. Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science. 312:1223-1227.
28. Komori, T., et al. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:755-764.
29. Lengner, C.J., et al. 2005. Nkx3.2-mediated repression of Runx-2 promotes chondrogenic differentiation. J. Biol. Chem. 280:15872-15979.
30. Kuznetsov, S.A., et al. 2004. The interplay of osteogenesis and hematopoiesis: expression of a constitutively active PTH/PTHrP receptor in osteogenic cells perturbs the establishment of hematopoiesis in bone and of skeletal stem cells in the bone marrow. J. Cell Biol. 167:1113-1122.
31. Wang, L., Liu, Y., Kalajzic, Z., Jiang, X., and Rowe, D.W. 2005. Heterogeneity of engrafted bone-lining cells after systemic and local transplantation. Blood. 106:3650-3657.
32. Elsubeihi, E.S., Bellows, C.G., Jia, Y., and Heersche, J.N. 2007. Ovariectomy of 12-month-old rats: effects on osteoprogenitor numbers in bone cell populations isolated from femur and on histomorphometric parameters of bone turnover in corresponding tibia. Cell Tissue Res. 330:515-526.
33. Sheng, M.H., et al. 1999. Histomorphometric studies show that bone formation and bone mineral apposition rates are greater in C3H/HeJ (high-density) than C57BL/6J (low-density) mice during growth. Bone. 25:421-429.
34. Barnes, G.L., et al. 2003. Osteoblast-related transcription factors Runx-2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res. 63:2631-2637.
35. Delmas, P.D. 2002. Treatment of postmenopausal osteoporosis. Lancet. 359:2018-2026.
36. Bilezikian, J.P. 2006. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N. Engl. J. Med. 355:2278-2281.
37. Tian, E., et al. 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349:2483-2494.
38. Yaccoby, S., et al. 2006. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 109:2106-2111.
39. Hideshima, T., et al. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:3071-3076.
40. Zarrinkalam, K.H., Kuliwaba, J.S., Martin, R.B., Wallwork, M.A., and Fazzalari, N.L. 2005. New insights into the propagation of fatigue damage in cortical bone using confocal microscopy and chelating fluorochromes. Eur. J. Morphol. 42:81-90.
41. Pierroz, D.D., Bouxsein, M.L., Rizzoli, R., and Ferrari, S.L. 2006. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone. 39:260-267.
42. Pratap, J., et al. 2003. Cell growth regulatory role of Runx-2 during proliferative expansion of preosteoblasts. Cancer Res. 63:5357-5362.
43. Vallet, S., et al. 2007. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesisand inhibits the interaction of multiple myeloma cells and osteoclasts. Blood. 110:3744-3752.